Oncology News

Researchers reported excellent 10-year outcomes among patients with hepatocellular carcinoma that was downstaged to within Milan criteria prior to liver transplant, according to a multicenter analysis published in JAMA Surgery.

Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according to data published in Cell Metabolism.

Hepatocellular carcinoma surveillance was underutilized in more than 80% of patients with cirrhosis, with lack of clinician orders and lack of patient adherence cited as common screening barriers, according to a study in JAMA Network Open.

There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open.

The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma.

Living-donor liver transplantation may be a viable option for patients with unresectable, liver-confined colorectal cancer liver metastases, according to a study published in JAMA Surgery.

Nonalcoholic fatty liver disease correlated with lower hepatocellular carcinoma surveillance receipt, early-stage detection and poorer survival compared with other HCC etiologies, according to research.

The AGA published 11 recommendations for systemic therapy in patients with hepatocellular carcinoma, which were featured in Gastroenterology.

The FDA granted orphan drug designation to two investigational T-cell immunotherapies for the treatment of advanced hepatocellular carcinoma.